Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. The 8 average consequence score is above the beat benchmark of 5.7 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Candida auris
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. The 8 average consequence score is above the beat benchmark of 5.7 in the same window. Each story carries 2 original sources on average, compared with 3.2 for the broader beat in this window. We currently track 1 Healthcare story that mention Candida auris, all published on February 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Candida auris. Shared-story counts are live from our verified record — not editorial picks.
New York health officials have issued a high-priority alert regarding the rapid spread of highly drug-resistant fungal infections across the state's healthcare infrastructure. These pathogens, including Candida auris, pose a severe threat to immunocompromised patients and are increasingly evading standard antifungal treatments.